Company milestones

Company History

2019 / 12
    Completed D round of capital increase.
2019 / 11
    Participated in 2019 CONTRAST MEDIA RESEARCH SYMPOSIUM and was invited to give a speech on “Super paramagnetic iron oxide nanoparticles (IOP) modified with polyethylene glycol in clinical phase two MRI imaging diagnosis of liver cancer patients.”
2018 / 11
     Won the "15th National Innovation Award-Enterprise Innovation Award".
2018 / 07
     Won the 2018 Taipei Biotechnology Award - New Technology Award / Silver Award.
2018 / 06
     Completed C round of capital increase.
2018 / 05
     MegaPro Biomedical's new drug IOP injection-MPB-1514 was notified by the US FDA to carry out Phase II clinical trials.
2018 / 04
     The Phase 2 clinical trial of MegaPro Biomedical's new drug IOP injection-MPB-1514 has been submitted to the US FDA for review.
2018 / 04
     Completed Phase 1b clinical trial of IOP injection-MPB-1523 at Taipei Veterans General Hospital.
2018 / 02
     MegaPro Biomedical's new drug IOP injection-MPB-1523 was notified by the Taiwan TFDA of its approval for the implementation of clinical phase 2 trials.
2018 / 01
     MegaPro Biomedical's new drug IOP injection-MPB-1523 was notified by the US FDA of its approval to carry out clinical phase 2 trials.
2017 / 12
     MegaPro Biomedical's new drug IOP injection-MPB-1523 was notified by the Taiwan TFDA to be approved for the clinical Phase 1b trial.
2017 / 08
     Hsinchu Science Park Bureau has approved the company to settle into the science park.
2017 / 06
     Completed the IOP injection-MPB-1523 clinical phase 1 clinical trial closing report.
2016 / 12
     Completed Phase I trial of IOP injection-MPB-1523 at Taipei Veterans General Hospital.
2016 / 12
     Wins the 13th National Startup Award-Startup Enterprise Award.
2016 / 10
     Completed B round of capital increase.
2016 / 03
     The Phase I trial of IOP injection-MPB-1514 was launched at Taipei Veterans General Hospital.
2016 / 03
     IOP injection was awarded the project subsidy of the A+ Enterprise Innovation R&D Chain Quenching Program-Fast Review Clinical Trial Program (Fast track) project of the Ministry of Economic Affairs' Science and Technology Research and Development Project.
2016 / 02
    The Phase I trial of IOP injection-MPB-1523 was launched at Taipei Veterans General Hospital.
2016 / 02
     Approved by the Ministry of Economic Affairs as a new biotechnology company.
2016 / 01
      Selected as an index case by the Taiwan Pharmaceutical Inspection Center (CDE).
2015 / 12
     MegaPro Biomedical's research and development of a new Chinese medicine MPB-1523 was notified by Taiwan's TFDA of its approval the implementation of Phase I clinical trial (Phase I).
2015 / 08
     To process and file for changes in the company business operations, including Western medicine wholesale, Western medicine retail, medical equipment wholesale, medical equipment retail, and drug inspection.
2015 / 08
     Finalist of Rookie Award for Biomedical Agronomy Draft Contest.
2015 / 01
     Complete round A of capital increase.
2015 / 01
     The company team is a spin-off by the Industrial Research Institute.
2014 / 11
    Founded.